Literature DB >> 16290267

Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis.

Maciej Jurynczyk1, Anna Jurewicz, Bartosz Bielecki, Cedric S Raine, Krzysztof Selmaj.   

Abstract

Oligodendrocytes (OLs) fail to regenerate myelin destroyed by the immune attack in multiple sclerosis (MS) and lesion areas are eventually largely occupied by astrocytic scar tissue. Loss of OLs in MS does not account for the limited myelin repair as lesions contain a considerable number of OL precursor cells (OPC). Activation of the Notch pathway has been shown to provide inhibitory signals for OPC and to hamper their ability to produce myelin during CNS development. Here we show that gamma-secretase inhibition of Notch signaling within OL of CNS of SJL/J mice with experimental autoimmune encephalomyelitis (EAE) significantly enhanced clinical recovery and in the CNS, promoted remyelination and reduced axonal damage. Functional assays confirmed decreased Notch signaling in inhibitor-treated groups. Therefore, gamma-secretase inhibition led to an environment more conducive to myelin repair and axonal survival. Our results suggest that manipulation of the environment associated with Notch activation in the mature CNS provides a promising therapeutic target in MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16290267     DOI: 10.1016/j.jneuroim.2005.10.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  38 in total

Review 1.  Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.

Authors:  Martin Stangel; Corinna Trebst
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Re-expression of a developmentally restricted potassium channel in autoimmune demyelination: Kv1.4 is implicated in oligodendroglial proliferation.

Authors:  Eva Herrero-Herranz; Luis A Pardo; Gertrude Bunt; Ralf Gold; Walter Stühmer; Ralf A Linker
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

Review 3.  Neuroprotection and neuroregeneration in multiple sclerosis.

Authors:  Martin Stangel
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 4.  Myelin regeneration in multiple sclerosis: targeting endogenous stem cells.

Authors:  Jeffrey K Huang; Stephen P J Fancy; Chao Zhao; David H Rowitch; Charles Ffrench-Constant; Robin J M Franklin
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 5.  An overview of notch signaling in adult tissue renewal and maintenance.

Authors:  Chihiro Sato; Guojun Zhao; Ma Xenia G Ilagan
Journal:  Curr Alzheimer Res       Date:  2012-02       Impact factor: 3.498

6.  [New therapeutic strategies for remyelination in multiple sclerosis].

Authors:  D Kremer; H-P Hartung; M Stangel; P Küry
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 7.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

Review 8.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

9.  Targeting Notch signaling in autoimmune and lymphoproliferative disease.

Authors:  David T Teachey; Alix E Seif; Valerie I Brown; Marlo Bruno; Ralph M Bunte; Yueh J Chang; John K Choi; Jonathan D Fish; Junior Hall; Gregor S Reid; Theresa Ryan; Cecilia Sheen; Patrick Zweidler-McKay; Stephan A Grupp
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

10.  p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation.

Authors:  David Kremer; André Heinen; Janusz Jadasz; Peter Göttle; Kristin Zimmermann; Philipp Zickler; Sebastian Jander; Hans-Peter Hartung; Patrick Küry
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.